Literature DB >> 3013349

Transferrin receptor is inversely correlated with estrogen receptor in breast cancer.

S E Tonik, J E Shindelman, H H Sussman.   

Abstract

The transferrin receptor (TfR) has been identified as a marker for proliferation in cells in culture and can be accurately quantitated by specific radioimmunoassay. This study directly quantifies levels of TfR and compares them to levels of estrogen receptor (ER) and progesterone receptor (PgR) in biopsy material obtained from patients with infiltrating ductal carcinoma of the breast. A comparison of ER and TfR levels displayed an exponential distribution which was log-normalized to yield a linear inverse relationship (r = -.44). Although ER was strongly correlated with PgR, there was no correlation pattern between TfR and PgR. Multiple regression analysis indicated that 73% of ER levels could be predicted by a combination of the other two markers, PgR (representing degree of differentiation) and TfR (representing growth rate). Transferrin receptor levels were also found to be correlated (p less than .05) with menopausal status, with tumors from premenopausal patients exhibiting higher levels, whereas the opposite pattern was shown for estrogen receptor levels (p less than .02). Neither steroid receptor nor transferrin receptor levels were correlated to stage of disease or presence of nodal involvement. Addition of TfR level as an independent marker for proliferation may facilitate the decision-making process in the treatment of individual cases of carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013349     DOI: 10.1007/bf01806791

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  40 in total

1.  Combined radiolabel-binding and immunocytochemical evaluation of receptor-ligand interactions. Studies of transferrin receptors on activated lymphocytes.

Authors:  G M Galbraith; R M Galbraith
Journal:  Biochem J       Date:  1981-10-15       Impact factor: 3.857

2.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

3.  Placental transferrin receptor. Evaluation of the presence of endogenous ligand on specific binding.

Authors:  H Tsunoo; H H Sussman
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

4.  Cancer statistics, 1982.

Authors:  E Silverberg
Journal:  CA Cancer J Clin       Date:  1982 Jan-Feb       Impact factor: 508.702

5.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

6.  Prognostic factors in patients with stage I, estrogen receptor-negative carcinoma of the breast. A clinicopathologic study.

Authors:  T W Bauer; D O'Ceallaigh; J C Eggleston; G W Moore; R R Baker
Journal:  Cancer       Date:  1983-10-15       Impact factor: 6.860

7.  Progesterone and estrogen receptors as prognostic variables in breast cancer.

Authors:  B H Mason; I M Holdaway; P R Mullins; L H Yee; R G Kay
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

8.  Prognostic value of estrogen receptor determinations in patients with breast cancer.

Authors:  M A Rich; P Furmanski; S C Brooks
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

9.  Cell proliferation and its relationship to clinical features and relapse in breast cancers.

Authors:  C Gentili; O Sanfilippo; R Silvestrini
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

10.  Prediction of early course of breast carcinoma by thymidine labeling.

Authors:  J S Meyer; E Friedman; M M McCrate; W C Bauer
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

View more
  7 in total

1.  Src regulates Tyr(20) phosphorylation of transferrin receptor-1 and potentiates breast cancer cell survival.

Authors:  Jinlong Jian; Qing Yang; Xi Huang
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

Review 2.  Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.

Authors:  Hira Choudhury; Manisha Pandey; Pei Xin Chin; Yee Lin Phang; Jeng Yuen Cheah; Shu Chien Ooi; Kit-Kay Mak; Mallikarjuna Rao Pichika; Prashant Kesharwani; Zahid Hussain; Bapi Gorain
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 3.  Mitogenic regulation of normal and malignant breast epithelium.

Authors:  M E Lippman; R B Dickson
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct

4.  Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients.

Authors:  Christopher J Greene; Kristopher Attwood; Nitika J Sharma; Kenneth W Gross; Gary J Smith; Bo Xu; Eric C Kauffman
Journal:  Oncotarget       Date:  2017-11-06

Review 5.  [The role of ferroptosis in chronic diseases].

Authors:  Junyi Chen; Xiang Yang; Xuexian Fang; Fudi Wang; Junxia Min
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

6.  Contribution of three-dimensional architecture and tumor-associated fibroblasts to hepcidin regulation in breast cancer.

Authors:  Nicole Blanchette-Farra; Daniel Kita; Anna Konstorum; Lia Tesfay; David Lemler; Poornima Hegde; Kevin P Claffey; Frank M Torti; Suzy V Torti
Journal:  Oncogene       Date:  2018-04-26       Impact factor: 9.867

Review 7.  Emerging Mechanisms and Disease Implications of Ferroptosis: Potential Applications of Natural Products.

Authors:  Chun Ge; Sujie Zhang; Huiwen Mu; Shaojun Zheng; Zhaoyi Tan; Xintong Huang; Chen Xu; Jianjun Zou; Yubing Zhu; Dong Feng; Jiye Aa
Journal:  Front Cell Dev Biol       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.